Business
Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)
New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN). The research summary below is from a report commissioned by Optimi Health Corp. and produced by Diamond Equity Research.The in-depth 40-page initiation report includes detailed information on Optimi Health’s business model, services, industry overview, financials,
About this update from Optimi Health Corp.
[{"type":"text","content":"New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN). The research summary below is from a report commissioned by Optimi Health Corp. and produced by Diamond Equity Research.The in-depth 40-page initiation report includes detailed information on Optimi Health’s business model, services, industry overview, financials, management profile, and risks.","length":530,"tagName":"p"},{"type":"text","content":"The full research report is available below.","length":44,"tagName":"p"},{"type":"text","content":"Optimi Health Initiation of Coverage","length":36,"tagName":"p"},{"type":"text","content":"Highlights from the report include:","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Optimi Is One of the Few Fully Licensed, Commercial-Stage Psychedelic Manufacturers: Optimi holds a Health Canada Drug Establishment Licence (DEL), GMP certification, a Dealer’s Licence, and a Class A Precursor Licence, enabling legal manufacture, possession, and export of MDMA and psilocybin. This places the company among a very limited global cohort capable of supplying pharmaceutical-grade psychedelics for prescription use. Most listed peers remain pre-commercial despite materially higher market capitalizations. Importantly, Optimi’s licences authorize both finished-dose products and APIs, providing flexibility across clinical supply, prescription sales, and future DMF-linked regulatory filings.","length":707,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":707,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"High-Margin, Fixed-Cost GMP Infrastructure Creates Operating Leverage Potential: We model approximately 75% long-term gross margins, driven by in-house GMP manufacturing, limited variable costs, and protocol-defined dosing. With annual capacity of approximately 1 million MDMA capsules and 1 million psilocybin capsules, current utilization remains below 1%, implying meaningful margin expansion as patient volumes scale without incremental capex. Management estimates EBITDA breakeven at approximately 1,000 patients per month. At steady-state utilization, this infrastructure supports an illustrative revenue...